Squarepoint
SLS icon

Squarepoint’s SELLAS Life Sciences SLS Stock Holding History

Squarepoint’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$316K Buy
74,751
+61,466
+463% +$275K ﹤0.01% 3664
2025
Q4 		$50.1K Sell
13,285
-32,895
-71% -$63.9K ﹤0.01% 4130
2025
Q3 		$74.3K Buy
46,180
+30,058
+186% +$53.5K ﹤0.01% 4168
2025
Q2 		$35.3K Buy
+16,122
New +$24.7K ﹤0.01% 4349
2021
Q1 		– Sell
-10,081
Closed -$59K – 3567
2020
Q4 		$59K Buy
+10,081
New +$40.3K ﹤0.01% 2792
2020
Q3 		– Sell
-32,406
Closed -$95K – 2816
2020
Q2 		$95K Buy
+32,406
New +$87.9K ﹤0.01% 2024
2019
Q4 		– Sell
-1,207
Closed -$7K – 2770
2019
Q3 		$7K Buy
+1,207
New +$8.89K ﹤0.01% 2284
2017
Q3 		– Sell
-14
Closed -$12K – 1856
2017
Q2 		$12K Buy
+14
New +$12.2K ﹤0.01% 1490

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Squarepoint's SLS Position: Q1 2026 in Review

Squarepoint increased its SELLAS Life Sciences (SLS) stake by 463% in Q1 2026, buying an estimated $275K and bringing the position to 74,751 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Squarepoint first reported a position in SLS in Q2 2017 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Squarepoint held 74,751 shares of SELLAS Life Sciences worth $316K as of Q1 2026.
  • Squarepoint bought 61,466 SELLAS Life Sciences shares in Q1 2026, an estimated $275K.
  • SELLAS Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3664 holding.
  • Squarepoint first reported a position in SELLAS Life Sciences in Q2 2017 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.